Security
Attovia Therapeutics, Inc. Common Stock · ATTO
ATTONASDAQCommon stockCurrentCIK 2058707Updated Oct 9, 2026
ATTO price & chart
Loading TradingView…
NASDAQ:ATTO on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. Our lead pipeline candidates target commercially validated pathways and are designed through our ATTOBODY biologics platform to deliver improved treatments relative to the current standards of care. Leveraging our ATTOBODY platform, we have nominated three product candidates within our first two years, including one currently in the clinic, ATTO-1310. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31 (IL-31) that completed dosing in a Phase 1 clinical trial in healthy volunteers (HVs) and patients in the first quarter of 2026. ATTO-2306 is an ATTOBODY-based bispecific targeting interleukin-13 (IL-13) and IL-31 that is in investigational new drug (IND)-enabling studies, and we expect to commence a Phase 1 clinical trial in the first half of 2027. Lastly, ATTO-1091 is our trispecific ATTOBODY-based Fc fusion protein that is designed to block TL1A, IL-23 and integrin a4ß7 simultaneously, and is currently in IND-enabling studies.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Show 5 more recent filings
Offerings
Registration 333-297452
- Gross proceeds
- 289000000.0
- Net proceeds
- 268770000.0
- Deal price
- 17.0
- Shares
- 17000000
- Offering price
- $17.00
- Ticker
- ATTO
Underwriters: Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets
Filing attachments
atto-ex99_1.htm · 8-K · 2026-09-02
EX-99.1 2 atto-ex99_1.htm EX-99.1 EX-99.1 Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of ATTO-1310 in chronic pruritus of unknown origin and high-itch AD planned for 1H 2027 Phase 1 initiation for ATTO-2306 and ATTO-1091 planned in 1H 2027 Upsized Initial Pu…
Read attachment ↗d40469dex107.htm · S-1/A · 2026-07-29
Exhibit 10.7 A TTOVIA T HERAPEUTICS, I NC. July 20, 2026 Petter Veiby Sent via email RE: Continued Employment with Attovia Therapeutics, Inc. Dear Petter: This letter agreement (“Agreement”) amends and restates the offer letter between you and Attovia Therapeutics, Inc. (the “Company”), dated on or about June 19, 2023 (the “Prior Agreement”) and sets forth the terms of your continued employment with the Company or a subsidiary of the Company. This Agreement is effective as of the closing …
Read attachment ↗d40469dex41.htm · S-1/A · 2026-07-29
Exhibit 4.1 INCORPORATED UNDER THE CUSIP 04987L 10 2 LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: FIDELITY is the record holder of STOCK FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF ATTOVIA THERAPEUTICS, INC. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly TRANSFER endorsed. This Certificate is not valid until counters…
Read attachment ↗d40469dex42.htm · S-1 · 2026-07-14
Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of March 31, 2025, by and among Attovia Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”. RECITALS WHEREAS, c…
Read attachment ↗d40469dex991.htm · S-1 · 2026-07-14
Exhibit 99.1 Consent of LifeSci Consulting Attovia Therapeutics, Inc. 1091 Industrial Road, Suite 310 San Carlos, California 94070 We, LifeSci Consulting, hereby consent to the references to our name and logos, and to the quotation of data and statements from the research reports dated August 2025 entitled “Pruritus Disease Opportunity Assessment for ATTO-1310: Final Deliverable,” October 2025 entitled “Pruritus Disease Opportunity Assessment for ATTO-1310: Cholestatic Pruritus Expansion” a…
Read attachment ↗